We are always interested in bringing excellent content to our clients and the scientific community. We are partnering with BioInsights to present this webinar to educate and inform on this important topic.
Both immunotherapy and regenerative medicine are experiencing explosive growth. It was a pleasure to learn about the advancements in these fields at two excellent conferences, the CAR-TCR Summit organized by Hanson Wade, and the Cell and Gene Meeting on the Mesa sponsored by the Alliance of Regenerative Medicine.
When we talk about One Health, just what do we mean? On its own, the phrase can be interpreted to mean many things, but for what we do in the biotechnology field, it encompasses human and animal health and disease, along with related environmental and epidemiological components. Essentially, it defines how people and animals interact with, and within, our shared environments, especially in reference to health and developing treatments for diseases.
When we talk about the use of CRISPR-Cas9 technology, it’s usually in the context of developing treatments for human diseases. But there’s another aspect to the technology that has potential to have just as much impact on our lives: its use in the genetic modification of food crops.
Demand for CMO fermentation capacity has exploded in the past couple of years, and it’s become very important that we find new ways to meet industry demand. That’s a big reason we’re seeing single-use fermentation (SUF) technology as an accelerating trend in the industry, especially for us at Aldevron.
We never know where roads will lead us, though one roadmap we’re proud of providing is one of internships, helping develop scientific talent in our growing biotechnology industry.
It is great to be able to provide the opportunity and watch students getting involved in the industry while being able to apply what they are learning at college to the work going on in the field.
This is a benefit to them, our company and the industry at large, as they will be the next generation of scientific talent helping drive breakthroughs in research and providing novel health care.
By Krishanu Saha, Ph.D., Department of Biomedical Engineering & Wisconsin Institute for Discovery, University of Wisconsin-Madison
At the University of Wisconsin - Madison, one focus of our group is understanding and optimizing CRISPR-Cas9 gene editing for therapeutic and disease modeling applications. To conduct our research, we need reliable, consistent and highly efficient Cas9 protein.
Model system for Cas9 gene editing
To perform targeted gene editing, the Cas9 protein, which cuts the genome, and a guide RNA (gRNA) that encodes where in the genome to cut, need to be complexed together into a ribonuclear protein (RNP) complex and transfected to cells to reach the nucleus. Once the DNA is cut, imprecise DNA repair may cause disruption at the cut site, which can result in knock out of a gene.
Excellent scientific talks and great weather were on tap when I attended the 2017 Cell & Gene Therapy World in Miami in January. Ed Field from BioRestorative Therapies started off with the top events of 2016, which was populated with some sizable deals.
Starting out, Aldevron founders Michael Chambers and John Ballantyne had one thing in common besides being fascinated with biotechnology and its applications in health care. They are both graduates of North Dakota State University (NDSU) in Fargo.
By Mark Osborn, Ph.D., Minnesota Stem Cell Institute, University of Minnesota
CRISPR/Cas9 is a vital part of our research at the University of Minnesota and the Cas9 recombinant protein, used at high concentration, has allowed for highly efficient modification of T-cells.
By introducing a Cas9 nuclease guide RNA complex (RNP), we target a specific spot in the genome, where the nuclease cuts the DNA. The DNA break is repaired in one of two ways: homologous recombination, which is high-fidelity, or non-homologous endjoining (NHEJ), which is more error-prone.